Company
Every investor coverage indicates participated in a round BioCina raised.
Companies BioCina acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Mark W. Womack | CEO | @AuManufacturing |
Stories naming BioCina. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Entropy Neurodynamics has agreed with UCSF to run a US Phase 2 trial of its psilocin drug TRP-8803 against escitalopram in young adults with depression, pending FDA clearance, with Swinburne and BioCina supporting.
A South Australian biologics manufacturer will help scale a grant-backed university resin technology for purifying biopharmaceutical medicines from laboratory to commercial production.
Vaccine maker BioCina is partnering with defence and university researchers on a project to create immunisations against biological warfare agents including Q Fever, tularaemia and melioidosis.
Techboard's monthly roundup cataloguing April 2022 Australian startup funding: megadeals, seed rounds, grants and crowdfunding, nine acquisitions, several ASX listings, and venture firms' fund news.